Pseudomonas aeruginosa Uses Dihydrolipoamide Dehydrogenase (Lpd) to Bind to the Human Terminal Pathway Regulators Vitronectin and Clusterin to Inhibit Terminal Pathway Complement Attack.

The opportunistic human pathogen Pseudomonas aeruginosa controls host innate immune and complement attack. Here we identify Dihydrolipoamide dehydrogenase (Lpd), a 57 kDa moonlighting protein, as the first P. aeruginosa protein that binds the two human terminal pathway inhibitors vitronectin and clu...

Full description

Bibliographic Details

Published in:	PLoS ONE
Main Authors:	Teresia Hallström, Melanie Uhde, Birendra Singh, Christine Skerka, Kristian Riesbeck, Peter F Zipfel
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2015-01-01
Online Access:	http://europepmc.org/articles/PMC4569481?pdf=render